Evidence brief · Supplement

Rapamycin (Sirolimus) for Human longevity

Evidence grade D — No outcome data yet

Overall grade
Grade D
Last revised
1
graded outcome
0
references listed

Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.

1 at grade D — 1 graded row

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Human longevityEvidence grade D

    No outcome data yet

    Unclearlow

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Thin evidence: Human longevity (grade D).

The evidence in words

The verdict

For human longevity, Rapamycin (Sirolimus) earns evidence grade D (unclear effect, low consistency) — the evidence does not support the claim. No outcome data yet

How it might work

It inhibits mTOR, the growth-and-nutrient-sensing pathway; dialing mTOR down mimics aspects of caloric restriction and boosts autophagy.

How to use it

Safety & cautions

Prescription-only for good reason: immunosuppression, mouth ulcers, impaired glucose tolerance, and lipid changes. Off-label longevity use should only happen under a knowledgeable physician.

Bottom line

The strongest lifespan-extending molecule known in animals, and a genuine frontier in human aging research — but a serious immunosuppressant drug, not a self-prescribed supplement.

Goes with

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.

Last revised . A grade is this entry's reading of the evidence, not medical advice.